| Budget Amount *help |
¥206,700,000 (Direct Cost: ¥159,000,000、Indirect Cost: ¥47,700,000)
Fiscal Year 2021: ¥23,660,000 (Direct Cost: ¥18,200,000、Indirect Cost: ¥5,460,000)
Fiscal Year 2020: ¥22,750,000 (Direct Cost: ¥17,500,000、Indirect Cost: ¥5,250,000)
Fiscal Year 2019: ¥24,180,000 (Direct Cost: ¥18,600,000、Indirect Cost: ¥5,580,000)
Fiscal Year 2018: ¥28,860,000 (Direct Cost: ¥22,200,000、Indirect Cost: ¥6,660,000)
Fiscal Year 2017: ¥107,250,000 (Direct Cost: ¥82,500,000、Indirect Cost: ¥24,750,000)
|
|---|
| Outline of Final Research Achievements |
Digestive tissues are subject to a variety of diseases, including tumors. However, due to the lack of analytical platforms, our understanding of the pathogenesis of human gastrointestinal tissues has lagged behind. We have been working to understand the pathogenesis of diseases and to develop new therapies using organoid technology, which enables in vitro cultivation of tissues with gastrointestinal diseases. We have established organoids from various gastrointestinal disease tissues, including ulcerative colitis, gastric cancer, colorectal cancer, pancreatic cancer, and endocrine cell carcinoma, and constructed a biobank such that researchers can utilize them. In addition, molecular profiling of disease organoids elucidated the biological mechanism underlying the diseases. We also employed genome editing technology and animal models to gain a better understanding of new gastrointestinal diseases.
|
